Cyclosporine A (CsA) is one of the most effective systemic drugs available for the treatment of psoriasis, as evidenced by the results\r\nof several randomized studies and by a prolonged experience in dermatological setting. In clinical practice, CsA is usually used for\r\nthe induction of psoriasis remission at a daily dose included in the range of 2.5ââ?¬â??5mg/kg and with intermittent short-termregimens,\r\nlasting on average 3ââ?¬â??6 months. The magnitude and rapidity of response are dose dependent, as well as the risk of development\r\nof adverse events. Therefore, the dose should be tailored to patientââ?¬â?¢s needs and general characteristics and adjusted during the\r\ntreatment course according to both the efficacy and tolerability. Some studies support the feasibility of pulse administration of CsA\r\nfor a few days per week for both the induction and the maintenance of response in psoriasis patients. This paper will review the\r\ndata on CsA regimens for plaque-type psoriasis and will focus the attention on dose, treatment duration, novel schedules, and role\r\nin combination therapies, including the association with biologicals.
Loading....